Literature DB >> 6390972

Duration of type I diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia.

M Lorenzi, N Bohannon, E Tsalikian, J H Karam.   

Abstract

The glucagon response to hypoglycemia, which fulfills a primary role toward restoring the plasma glucose level, is blunted or absent in most patients with type I diabetes. To identify predictive factors for this abnormality and for the capability of glycemic counterregulation, we investigated the relationship between the duration of diabetes and glucagon and glucose responses to insulin-induced hypoglycemia. In 18 type I diabetic patients with 1 through 28 years of disease who had no detectable autonomic neuropathy, individual glucagon increments after insulin hypoglycemia were inversely correlated with the duration of disease (r = -.53, P < .025). Patients with disease for ten or fewer years showed a glucagon rise that was lower than in controls but significantly higher than in patients with a duration of more than ten years. The plasma glucose rise after the nadir correlated with peak glucagon increments (r = .60, P < .01); eight of the nine patients with glycemic increments comparable to normals had had diabetes for ten years or less. Thus, having diabetes for more than ten years implied that not only were glucagon responses to insulin hypoglycemia severely compromised but also that the abrupt restoration of plasma glucose levels was impaired. These findings should be taken into account when establishing goals and modalities for tight metabolic control.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6390972      PMCID: PMC1021855     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  25 in total

1.  Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man.

Authors:  J Gerich; J Davis; M Lorenzi; R Rizza; N Bohannon; J Karam; S Lewis; R Kaplan; T Schultz; P Cryer
Journal:  Am J Physiol       Date:  1979-04

2.  Characterization of the glucagon response to hypoglycemia in man.

Authors:  J E Gerich; V Schneider; S E Dippe; M Langlois; C Noacco; J H Karam; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1974-01       Impact factor: 5.958

3.  Stimulation of glucagon secretion by epinephrine in man.

Authors:  J E Gerich; J H Karam; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1973-09       Impact factor: 5.958

4.  Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps.

Authors:  A Pietri; A L Ehle; P Raskin
Journal:  Diabetes       Date:  1980-08       Impact factor: 9.461

5.  Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.

Authors:  R A Rizza; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

6.  Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect.

Authors:  J E Gerich; M Langlois; C Noacco; J H Karam; P H Forsham
Journal:  Science       Date:  1973-10-12       Impact factor: 47.728

7.  Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes.

Authors:  S Madsbad; O K Faber; C Binder; P McNair; C Christiansen; I Transbøl
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

8.  Glucagon and catecholamine secretion during hypoglycemia in normal and diabetic man.

Authors:  J W Benson; D G Johnson; J P Palmer; P L Werner; J W Ensinck
Journal:  J Clin Endocrinol Metab       Date:  1977-03       Impact factor: 5.958

9.  Abnormalities of endogenous glucagon and insulin in unstable diabetes.

Authors:  C Reynolds; G D Molnar; D L Horwitz; A H Rubenstein; W F Taylor; N S Jiang
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

Review 10.  Diabetic autonomic neuropathy.

Authors:  B F Clarke; D J Ewing; I W Campbell
Journal:  Diabetologia       Date:  1979-10       Impact factor: 10.122

View more
  9 in total

1.  Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients.

Authors:  Dayu Lv; Marc D Breton; Leon S Farhy
Journal:  Diabetes Technol Ther       Date:  2013-08-26       Impact factor: 6.118

2.  Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.

Authors:  P A Bakhtiani; J El Youssef; A K Duell; D L Branigan; P G Jacobs; M R Lasarev; J R Castle; W K Ward
Journal:  J Diabetes Complications       Date:  2014-09-16       Impact factor: 2.852

3.  Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.

Authors:  Joseph El Youssef; Jessica R Castle; Parkash A Bakhtiani; Ahmad Haidar; Deborah L Branigan; Matthew Breen; W Kenneth Ward
Journal:  Diabetes Care       Date:  2014-08-19       Impact factor: 19.112

Review 4.  A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy.

Authors:  P A Bakhtiani; L M Zhao; J El Youssef; J R Castle; W K Ward
Journal:  Diabetes Obes Metab       Date:  2013-04-21       Impact factor: 6.577

5.  The UVA/PADOVA Type 1 Diabetes Simulator: New Features.

Authors:  Chiara Dalla Man; Francesco Micheletto; Dayu Lv; Marc Breton; Boris Kovatchev; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

6.  Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes.

Authors:  Aris Siafarikas; Robert J Johnston; Max K Bulsara; Peter O'Leary; Timothy W Jones; Elizabeth A Davis
Journal:  Diabetes Care       Date:  2012-06-14       Impact factor: 19.112

7.  Optimal regulation of blood glucose level in Type I diabetes using insulin and glucagon.

Authors:  Afroza Shirin; Fabio Della Rossa; Isaac Klickstein; John Russell; Francesco Sorrentino
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

8.  A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia.

Authors:  Joseph Chabenne; Maria Dimarchi Chabenne; Yan Zhao; Jay Levy; David Smiley; Vasily Gelfanov; Richard Dimarchi
Journal:  Mol Metab       Date:  2014-01-22       Impact factor: 7.422

9.  Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.

Authors:  Kathrin Herrmann; Steven C Brunell; Yan Li; Ming Zhou; David G Maggs
Journal:  Adv Ther       Date:  2016-04-12       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.